Drug Profile
Research programme: cancer therapeutics - AstraZeneca/Petrov Institute
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca; N.N. Petrov Institute of Oncology
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in World
- 12 Feb 2013 Early research in Cancer in World (unspecified route)